448 related articles for article (PubMed ID: 18068630)
1. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.
Zhao C; Blum J; Chen A; Kwon HY; Jung SH; Cook JM; Lagoo A; Reya T
Cancer Cell; 2007 Dec; 12(6):528-41. PubMed ID: 18068630
[TBL] [Abstract][Full Text] [Related]
2. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.
Schürch C; Riether C; Matter MS; Tzankov A; Ochsenbein AF
J Clin Invest; 2012 Feb; 122(2):624-38. PubMed ID: 22232214
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Jamieson CH; Ailles LE; Dylla SJ; Muijtjens M; Jones C; Zehnder JL; Gotlib J; Li K; Manz MG; Keating A; Sawyers CL; Weissman IL
N Engl J Med; 2004 Aug; 351(7):657-67. PubMed ID: 15306667
[TBL] [Abstract][Full Text] [Related]
4. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
5. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
6. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
9. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Zhou Z; Liu T; Zhang J
Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
[TBL] [Abstract][Full Text] [Related]
10. [Research Advance on Classic Wnt Pathway in Chronic Myelogenous Leukemia--Review].
Cao ZR; Chen XP; Hu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):350-353. PubMed ID: 32027302
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
12. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
13. Amide-linked local anesthetics preferentially target leukemia stem cell through inhibition of Wnt/β-catenin.
Ni J; Xie T; Xiao M; Xiang W; Wang L
Biochem Biophys Res Commun; 2018 Sep; 503(2):956-962. PubMed ID: 29932919
[TBL] [Abstract][Full Text] [Related]
14. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M
Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
Zhang B; Li L; Ho Y; Li M; Marcucci G; Tong W; Bhatia R
J Clin Invest; 2016 Mar; 126(3):975-91. PubMed ID: 26878174
[TBL] [Abstract][Full Text] [Related]
16. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
17. IGF-IR determines the fates of BCR/ABL leukemia.
Xie J; Chen X; Zheng J; Li C; Stacy S; Holzenberger M; Hu X; Zhang CC
J Hematol Oncol; 2015 Feb; 8(1):3. PubMed ID: 25648584
[TBL] [Abstract][Full Text] [Related]
18. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
19. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
20. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
